EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Approaches for C9ORF72-Related ALS: Current Strategies and Future Horizons

Marco Cattaneo, Eleonora Giagnorio iD, Giuseppe Lauria, Stefania Marcuzzo iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26136268 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Marco Cattaneo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Neuroalgology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy. Hauptthemen laut MEDLINE: C9orf72 Protein, Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health (RRC), CALabria HUB per Ricerca Innovativa ed Avanzata- CALHUB.RIA "Creazione di Hub delle Sci-enze della Vita", AriSLA foundation, "Bulb-Omics".

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the loss of upper and lower motor neurons. One of its major genetic causes is C9ORF72, where mutations lead to hexanucleotide repeat expansions in the C9ORF72 gene. These expansions drive disease progression through mechanisms, including the formation of toxic RNAs and the accumulation of damaged proteins such as dipeptide repeats (DPRs). This review highlights these pathogenic mechanisms, focusing on RNA foci formation and the accumulation of toxic DPRs, which contribute to neuronal damage. It also discusses promising targeted therapies, including small molecules and biological drugs, designed to counteract these specific molecular events. Small molecules such as G-quadruplex stabilizers, proteasome and autophagy modulators, and RNase-targeting chimeras show potential in reducing RNA foci and DPR accumulation. Furthermore, targeting enzymes involved in repeat-associated non-AUG (RAN) translation and nucleocytoplasmic transport, which are crucial for disease pathogenesis, opens new therapeutic avenues. Even some anti-viral drugs show encouraging results in preclinical studies. Biological drugs, such as antisense oligonucleotides and gene-editing technologies like CRISPR-Cas, were explored for their potential to specifically target C9ORF72 mutations and modify the disease’s molecular foundations. While preclinical and early clinical data show promise, challenges remain in optimizing delivery methods, ensuring long-term safety, and improving efficacy. This review concludes by emphasizing the importance of continued research and the potential for these therapies to alter the disease trajectory and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

C9orf72 ProteinAmyotrophic Lateral SclerosisHumansAnimalsDNA Repeat ExpansionGene EditingGenetic TherapyMutationOligonucleotides, Antisense

Stichwörter der Autor:innen

C9ORF72amyotrophic lateral sclerosisbiological drugssmall moleculestherapeutic strategies

Substanzen

C9orf72 ProteinC9orf72 protein, humanOligonucleotides, Antisense

Autor:innen und Institutionen

  • Neuroalgology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.
  • PhD Program in Pharmacological Biomolecular Sciences, Experimental and Clinical, University of Milan, 20133 Milan, Italy.
  • Neurology 4-Neuroimmunology and Neuromuscular Diseases, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.
  • Department of Medical Biotechnology and Translational Medicine, University of Milan, 20133 Milan, Italy.
  • Brain-Targeted Nanotechnologies (BraiNs) Lab, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.

ORCID-Profile: Eleonora Giagnorio, Stefania Marcuzzo

Förderung

  • Italian Ministry of Health (RRC)
  • CALabria HUB per Ricerca Innovativa ed Avanzata- CALHUB.RIA "Creazione di Hub delle Sci-enze della Vita"
  • AriSLA foundation, "Bulb-Omics"
  • the European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS,
  • CALabria HUB per Ricerca Innovativa ed Avanzata—CALHUB.RIA “Creazione di Hub delle Scienze della Vita”
  • AriSLA foundation, “Bulb-Omics”
  • European Union—Next Generation EU—NRRP M6C2—Investment 2.1 Enhancement and strengthening of biomedical research in the NHS

Zitieren

APA

Cattaneo, M., Giagnorio, E., Lauria, G., & Marcuzzo, S. (2025). Therapeutic Approaches for C9ORF72-Related ALS: Current Strategies and Future Horizons. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136268

Vancouver

Cattaneo M, Giagnorio E, Lauria G, Marcuzzo S. Therapeutic Approaches for C9ORF72-Related ALS: Current Strategies and Future Horizons. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136268

BibTeX
@article{Cattaneo2025,
  author = {Cattaneo, Marco and Giagnorio, Eleonora and Lauria, Giuseppe and Marcuzzo, Stefania},
  title = {Therapeutic Approaches for C9ORF72-Related ALS: Current Strategies and Future Horizons},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26136268}
}
Kostenlos starten →